David A. Hollander
2020
In 2020, David A. Hollander earned a total compensation of $648.8K as Chief Research and Development Officer at Aerie Pharmaceuticals, a 69% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $206,850 |
|---|---|
| Salary | $441,917 |
| Total | $648,767 |
Hollander received $441.9K in salary, accounting for 68% of the total pay in 2020.
Hollander also received $206.9K in non-equity incentive plan.
Rankings
In 2020, David A. Hollander's compensation ranked 10,239th out of 13,090 executives tracked by ExecPay. In other words, Hollander earned more than 21.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,239 out of 13,090 | 22nd |
Division Manufacturing | 4,388 out of 5,621 | 22nd |
Major group Chemicals And Allied Products | 1,811 out of 2,254 | 20th |
Industry group Drugs | 1,584 out of 1,954 | 19th |
Industry Biological Products, Except Diagnostic Substances | 359 out of 411 | 13th |
Source: SEC filing on April 27, 2021.
Hollander's colleagues
We found five more compensation records of executives who worked with David A. Hollander at Aerie Pharmaceuticals in 2020.
2020
Vicente Anido
Aerie Pharmaceuticals
Chief Executive Officer
2020
Thomas Mitro
Aerie Pharmaceuticals
Chief Operating Officer
2020
Richard Rubino
Aerie Pharmaceuticals
Chief Financial Officer
2020
Casey Kopczynski
Aerie Pharmaceuticals
Chief Scientific Officer
2020
John LaRocca
Aerie Pharmaceuticals